Connect with us


Retinal Disease Therapeutics Market to Reach US$ 21,318.0 Mn by 2026 at a CAGR Of 6.6%


The Global Retinal Disease Therapeutics Market is likely to expand at an impressive rate driven by recent government participation towards the prevention and control of retinal diseases. According to a report published by Fortune Business Insights, titled “Retinal Disease Therapeutics: Global Market Analysis, Insights, and Forecast, 2019-2026,” the market is likely to reach US$ 21,318.0 Mn by the end of 2026. The market was valued at US$ 11,044.2 Mn in 2018 and is likely to witness a CAGR of 8.6% in the forecast period.

Browse Complete Report Details @

The Global Retinal Disease Therapeutics Market is consolidated in nature, with only a handful of market players accounting for the maximum share of the market. With consolidation, it is becoming increasingly difficult for newer market entrants to establish a stronghold or derive immediate success. Therefore the global market is boosted by-products and concepts introduced by existing companies.

  1. Hoffmann-La Roche AG’s ‘Lucentis’ is Gaining Increasing Popularity

The diabetic retinopathy is a severe kind of disorder that has accounted for the majority of cases of blindness in the US. Lucentis was an instant hit among healthcare professionals after it was backed by a series of clinical trials and approvals from the National Institute of Health (NIH).

One such instance of this development is the “Lucentis” therapy, put forward by F. Hoffmann-La Roche AG. Lucentis was introduced to provide therapeutic advice and development of products for patients suffering from chronic disease. In 2017, the Food and Drug Administration (FDA) approved Lucentis for diabetic retinopathy.

Some of the Main Key Players Covered in the Report

  • Merck
  • Novartis
  • Allergan
  • Roche
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical

Sample PDF Brochure @

Excellent clinical effects of Lucentis have led to a subsequent rise in demand for medicine among patients. The increasing demand has contributed to the growth of the global retinal disease therapeutics market and is likely to favor the market in the forthcoming years.


By Disease Indication

  • Macular Degeneration
  • Diabetic Retinopathy
  • Diabetic Macular Edema
  • Retinal Vein Occlusion

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

North America to Emerge Dominant in the Forecast Period

The increasing government investment towards research and development of retinal disease drugs and diagnostic devices is enabling growth in the retinal diseases therapeutics market in North America. North America has emerged dominant in the global retinal disease therapeutics market in recent years. The Retinal Disease Therapeutics Market in North America was valued at US$ 4056.5Mn in 2018 and is likely to increase in the coming years.

Improved health infrastructures, increasing patient pool, and favorable health reimbursement policies are some of the factors that are likely to boost the regional market in the forthcoming years. High prevalence of retinal diseases in the Asia Pacific is a major reason why this region is estimated to rise with the highest CAGR in the forecast period.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook and SWOT analysis:

1. Introduction

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

4. Key Insights

4.1 Recent industry developments such as mergers and acquisitions

4.2 Regulatory scenario for key countries

4.3 Prevalence of Key RetinalDiseases, in Major Countries

5. Global RetinalDisease Therapeutics Market Analysis, Insights, and Forecast, 2015-2026

5.1. Key Findings / Summary

5.2 Market Analysis, Insights andForecast By Disease Indication

5.2.1 macular degeneration

5.2.2 DiabeticMacular Edema

5.2.3 diabetic retinopathy

5.2.4 retinal vein Occlusion

5.2.5 Others

5.3. Market Analysis, Insights and Forecast By End User

5.3.1 hospital pharmacy

5.3.2 retail pharmacy

5.3.3 Others

5.4. Market Analysis, Insights and Forecast By Region

5.4.1 NorthAmerica

5.4.2 Europe

5.4.3 AsiaPacific

5.4.4 Latin America

5.4.5 MiddleEast and Africa

More Trending Topics from Future Business Insights:

Cardiovascular Stents Market 2019 Industry Size, Trends, Global Growth, Insights and Forecast Research Report 2025

Coronary Stents Market 2019 Leading Company Analysis, Global Share, Growth, Size, Opportunities, Trends, Regional OverviewForecast To 2025

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us

Fortune Business Insights Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.


US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

Email: [email protected]


VentureIsrael Launches New Venture Capital Fund


VentureIsrael announced today the launch of a new venture capital fund, which will invest in Israel based, early stage deep-tech start-ups. The fund investment strategy focuses on the companies with clear-cut technological advantages, an experienced management team and a flexible business strategy.

The fund first investments are a secure quantum communications system, an AI market research solution and a next-generation correspondent banking platform.

VentureIsrael is managed by five partners “ all investment experts with diverse backgrounds: Michael Harte – former COO of Santander UK and Barclays; Roman Gold, Gadi Isaev and Alexander Zarankin of JSCapital “ the Israeli investment platform; and Igor Turkin of Investment Management Group.

The Israeli innovation industry is demonstrating phenomenal growth potential even given the current turbulent economic environment, said Roman Gold. In the first half of 2020, Israeli start-ups attracted a record of $5.25 billion investment capital, while the total amount of exits approached $7 billion. We also see that the demand for early-stage capital is growing faster than the amount of the funding available “ therefore our aim is to find the right place in that niche of the market.

Being a part of Israeli start-up ecosystem and having closed large number of successful investment deals, we have consistently observed the importance of a clear technological advantage in a companys ability to stand out from the competition. Thats the reason our funds investment strategy will focus on deep-tech companies, said Gadi Isaev.

VentureIsrael will also pay close attention to the Enterprise Software segment of Israeli early stage start-ups. Worldwide, we see in increasing corporate demand for digital transformation. The Israeli market has long established itself as an influential and effective provider of innovative solutions for the corporate segment and our fund will seek out the best opportunities in that field, said Igor Turkin.

VentureIsraels initial closing has attracted substantial attention from private and institutional investors globally. The fund headquarters are based in Tel-Aviv, with an international subsidiary in London.

The fund final closing is expected in the first half of 2021.

For press inquiries or additional information, please contact:

Gadi Isaev


[email protected]

Continue Reading


Global Artificial Ligaments and Tendons Market- Featuring Artelon, Cousin-Biotech, FX Solutions, and GROUP FH ORTHO Among Others


The artificial ligaments and tendons market is poised to grow by USD 15.54 million during 2020-2024, progressing at a CAGR of over 11% during the forecast period.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Download Free Sample Report on COVID-19 Recovery Analysis

The report on the artificial ligaments and tendons market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by advantages of artificial ligaments.

The artificial ligaments and tendons market analysis include the application segment and geography landscape. This study identifies the growing interest in R&D of tissue-engineered ligaments as one of the prime reasons driving the artificial ligaments and tendons market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The Artificial Ligaments and Tendons Market covers the following areas:

Artificial Ligaments and Tendons Market Sizing

Artificial Ligaments and Tendons Market Forecast

Artificial Ligaments and Tendons Market Analysis

Companies Mentioned

  • Artelon, Cousin-Biotech
  • FX Solutions
  • LARS
  • Mathys AG Bettlach
  • MorphoMed GmbH
  • Orthomed
  • Xiros Ltd.


Key Topics Covered:




  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
  • Value Chain Analysis


  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market outlook


  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition


  • Market segmentation by application
  • Comparison by application
  • Knee injuries – Market size and forecast 2019-2024
  • Shoulder injuries – Market size and forecast 2019-2024
  • Foot and ankle injuries – Market size and forecast 2019-2024
  • Other injuries – Market size and forecast 2019-2024
  • Market opportunity by application



  • Geographic segmentation
  • Geographic comparison
  • Europe – Market size and forecast 2019-2024
  • Asia – Market size and forecast 2019-2024
  • North America – Market size and forecast 2019-2024
  • ROW – Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity



  • Market drivers
  • Market challenges


  • Growing interest in R&D of tissue-engineered ligaments
  • Focus on development of 3D-printed human ligaments and tendons
  • Focus on biomechanical investigations of tendons and ligaments


  • Overview
  • Landscape disruption
  • Competitive scenario


  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Artelon
  • Cousin-Biotech
  • FX Solutions
  • LARS
  • Mathys AG Bettlach
  • MorphoMed GmbH
  • Orthomed
  • Xiros Ltd.


  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors


About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]


Continue Reading


Silver Bull Announces Closing of Initial Tranche of Private Placement For US$1.70 Million



VANCOUVER, British Columbia, Oct. 27, 2020 — Silver Bull Resources, Inc. (TSX: SVB; OTCQB: SVBL) (“Silver Bull” or the “Company”) is pleased to announce that it has completed the initial tranche of its previously announced private placement (the “Private Placement”). The initial tranche consisted of 3,623,580 units (the “Units”) of the Company at a price of US$0.47 per Unit for aggregate gross proceeds of US$1,703,083. Each Unit consists of one share of common stock in the Company (a “Common Share”) and one half of one transferable Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder to acquire one Common Share at a price of US$0.59 per Common Share until the fifth anniversary of closing of the initial tranche of the Private Placement.

Directors and management (and their affiliates) of the Company are purchasing 1,159,000 Units (approximately US$545,000) in the Private Placement.

The net proceeds of the Private Placement will be used by Silver Bull for general working capital purposes. The Company paid an aggregate finder’s fee on the initial tranche of the Private Placement of US$26,000 (1.5%).  

The second tranche of 319,000 Units (US$149,930) is expected to close on or about November 6, 2020.

All securities issued pursuant to the Private Placement are subject to a hold period under applicable Canadian securities laws, which will expire four months plus one day from the date of closing of the Private Placement, and will be restricted securities for purposes of U.S. securities laws.

The securities issued under the Private Placement have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. The Company plans to file a registration statement pursuant to the U.S. Securities Act which, when effective, will permit the resale of the Common Shares issued in connection with the Private Placement as well as the Common Shares issuable upon exercise of the Warrants. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of Silver Bull’s securities in the United States.

About Silver Bull: Silver Bull is a Vancouver-based mineral exploration company whose shares are listed on the TSX and trade on the OTCQB in the United States. Silver Bull recently signed an Option Agreement to acquire the Beskauga Copper-Gold Project, located in North Eastern Kazakhstan. This agreement is subject to on the ground due diligence, which will occur once safe travel to the region is allowed due to current COVID-19 related restrictions. In addition, Silver Bull owns the Sierra Mojada Project which is located 150 kilometers north of the city of Torreon in Coahuila, Mexico, and is highly prospective for silver and zinc. Sierra Mojada is currently under a joint venture option with South32 International Investment Holdings Pty Ltd.

On behalf of the Board of Directors “Tim Barry”

Tim Barry, CPAusIMM Chief Executive Officer, President and Director

INVESTOR RELATIONS: +1 604 687 5800 [email protected]  

Cautionary note regarding forward looking statements: Certain statements in this news release are “forward-looking” within the meaning of applicable securities legislation. Forward-looking statements can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements include, but are not limited to, statements relating to the expected use of proceeds from the Private Placement and the anticipated closing date for the second tranche of the Private Placement. Forward-looking statements are necessarily based upon the current belief, opinions and expectations of management that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and other contingencies. Many factors could cause the Company’s actual results to differ materially from those expressed or implied in the forward-looking statements. These factors include, among others, market prices, metal prices, availability of capital and financing, general economic, market or business conditions, as well as other risk factors set out under the heading “Risk Factors” in the Annual Report on Form 10-K for the year ended October 31, 2019, which is available on SEDAR at Investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Primary Logo

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News11 mins ago

VentureIsrael Launches New Venture Capital Fund

VentureIsrael announced today the launch of a new venture capital fund, which will invest in Israel based, early stage deep-tech...

gbafNews28 gbafNews28
News19 mins ago

Silver Bull Announces Closing of Initial Tranche of Private Placement For US$1.70 Million


gbafNews28 gbafNews28
News19 mins ago

Global Artificial Ligaments and Tendons Market- Featuring Artelon, Cousin-Biotech, FX Solutions, and GROUP FH ORTHO Among Others

The artificial ligaments and tendons market is poised to grow by USD 15.54 million during 2020-2024, progressing at a CAGR...

gbafNews28 gbafNews28
News39 mins ago

The U.S. EPA Announces New 5-Year Registration for XtendiMax® Herbicide, Bayer’s Low-Volatility Dicamba Product

Today, the U.S. Environmental Protection Agency (EPA) announced a new 5-year registration for XtendiMax herbicide with VaporGrip Technology, an important...

gbafNews28 gbafNews28
News47 mins ago

Visa to Acquire YellowPepper

Visa Inc. (NYSE: V) today announced it has signed a definitive agreement to acquire YellowPepper, a fintech pioneer with proprietary...

gbafNews28 gbafNews28
News49 mins ago

Joseph R. Biden Named Winner of Nickelodeon’s Kids Pick the President “Kids’ Vote”

The votes are in and kids have chosen Joseph R. Biden as the winner of Nickelodeons 2020 Kids Pick the...

gbafNews28 gbafNews28
News1 hour ago

PlanetWatch activates innovative air quality monitoring in two key Italian cities and announces grant from the Algorand Foundation

ST. GENIS-POUILLY, France, Oct. 28, 2020 /PRNewswire/ — PlanetWatch, a French startup which is leveraging the Algorand blockchain to build...

gbafNews28 gbafNews28
News1 hour ago

Atlas Crest Investment Corp. Announces Pricing of $500 Million Initial Public Offering

October 27, 2020 — Atlas Crest Investment Corp. (NYSE: ACIC.U, the “Company”) announced today that it priced its initial public...

gbafNews28 gbafNews28
News1 hour ago

Global Hemophilia Therapeutics Market- Featuring Bayer AG, CSL Ltd., F. Hoffmann-La Roche Ltd. Among Others

The hemophilia therapeutics market is poised to grow by USD 4.19 billion during 2020-2024 progressing at a CAGR of over...

gbafNews28 gbafNews28
News1 hour ago

Washington Federal Announces 22 Cent Per Share Cash Dividend

Today, the Board of Directors of Washington Federal, Inc. (Nasdaq: WAFD) (the Company), parent company of Washington Federal Bank, National...